For your adult patients with
MDS- or β-thalassemia–associated anemia
With Reblozyl—the first and only erythroid maturation agent—you can reduce or even eliminate patients’ red blood cell (RBC) transfusion dependence.1-3
Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia requiring transfusions associated with beta-thalassemia.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl, please refer to the EU Summary of Product Characteristics.